We use state-of-the-art technology to mechanistically investigate immune responses to cancer using preclinical laboratory modeling and translational studies of human cancer. We also leverage mathematical modeling and artificial intelligence to advance our understanding of tumor-immune interactions. Our goal is to translate findings into clinical trials to improve the efficacy of cancer immunotherapy for patients.